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Abstract
Background: The present study aims to evaluate the cost-effectiveness of extending the pre-2013 influenza
immunisation programme for high-risk and elderly individuals to those at low risk of developing complications
following infection with seasonal influenza.
Methods: We performed an economic evaluation comparing different extensions of the pre-2013 influenza
programme to seven possible age groups of low-risk individuals (aged 2–4 years, 50–64 years, 5–16 years, 2–4 and
50–64 years, 2–16 years, 2–16 and 50–64 years, and 2–64 years). These extensions are evaluated incrementally on
four base scenarios (no vaccination, risk group only with coverage as observed between 1995 and 2009, risk group
and 65+, and risk group with 75 % coverage and 65+). Impact of vaccination is assessed using a transmission
model built and parameterised from a previously published study. The study population is all individuals of all ages
in England and Wales representing an average total of 52.6 million people over 14 influenza seasons (1995–2009).
Results: The influenza programme (risk group and elderly) prior to 2013 is likely to be cost effective (incremental cost
effectiveness ratio: 7,475 £/QALY, net benefit: 253 M£ [15–829]). Extension to any one of the low-risk target groups
defined earlier is likely to be cost-effective. However, strategies that do not include vaccination of school-aged children
are less likely to be cost-effective. The most efficient strategy is extension to the 5–16 year age group while universal
vaccination (extension to all low-risk individuals over 2 years) will achieve the highest net benefit. While extension to
the 2–16 year age group is likely to be very cost effective, the cost-effectiveness of extensions beyond 2–16 years is
very uncertain. Extension to the 5–16 year age group would likely remain cost-effective even without herd immunity
effects to other age groups. As our study includes a strong historical component, our results depend on the efficacy of
the influenza vaccine remaining at levels similar to the ones achieved in the past over a long-period of time (assumed to
vary between 28 % and 70 % depending of the circulating strains and age groups).
Conclusions: Making use of surveillance data from over a decade in conjunction with a dynamic model, we find that
vaccination of children in the United Kingdom is likely to be highly cost-effective, not only for their own benefit but also
to reduce the disease burden in the rest of the community.
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Background
Most high income countries recommend that influenza
vaccination should be targeted at individuals at highest
risk of complications following influenza infection, such
as those with chronic heart or lung disease, metabolic or
renal disease, or immunodeficiencies [1], as well as the
elderly [2]. Recently, many countries have expanded
their definition of high risk to also include pregnant
women and the obese, and in 2012 the World Health
Organization (WHO) also recommended vaccination of
young children (particular those under 2 years of age) as
these also have a high risk of hospitalisation given infec-
tion [3]. However, these recommendations tend to con-
sider only the direct benefits of immunisation in
individuals (preventing serious complications). Wide-
spread vaccination might also impact on those who are
not directly reached by the programme, particularly if
vaccination is aimed at children, who are known to play
a key role in the spread of influenza [4–6]. Allocating
limited health resources to exploit indirect protection
could prove to be a more cost-effective alternative than
targeting only those at highest risk of disease but with
little role in the transmission of influenza [7].
Estimating the effectiveness and cost-effectiveness of
transmission-reducing influenza vaccination strategies is
complicated as it requires either large-scale community
randomised trials [8] or a mathematical model capable
of accurately simulating influenza transmission. Both ap-
proaches also need to run over many years as influenza
seasons vary in severity due to differences in the virus
subtype and intensity of circulation.
Recently, we have reconstructed the transmission dy-
namics of influenza A H3N2, H1N1, and influenza B in
the United Kingdom (UK) from 1995 to 2009 [9]. This
allowed us to test alternative vaccination scenarios and
evaluate their population impact over a large time frame.
This mathematical model formed the first part of a
series of three linked studies presented to the Joint
Committee on Vaccination and Immunisation in the
UK. These studies prompted the Joint Committee on
Vaccination and Immunisation to recommend, in the
summer of 2012, to extend the influenza immunisation
programme in the UK to all children aged 2–17 years
[10]. The second of these three studies, estimating the
burden of influenza, has been recently published [11].
We present here the last of these studies, which assimi-
lates the information from the earlier two aspects
(modelling and burden estimates) to look at the cost-
effectiveness of extending the seasonal influenza immun-
isation programme.
In particular, we explore whether vaccination of high-
risk individuals and the elderly (the strategy in place in
the UK since 2000) should be supplemented by vaccin-
ation of low-risk groups of different ages (from young
children to all 50–64 year olds). In so doing we assess
whether vaccination of transmitters (low-risk school
aged children) is a more efficient use of limited re-
sources than targeting groups with the highest disease
burden among those not yet targeted by the elderly- and
risk-group strategy (younger children and adults aged
50–64 years). Furthermore, in addition to the original
study and in order to generalise our findings to other
settings, we employed this framework to explore the cost
effectiveness of extending the programme to low-risk
groups under different counterfactual scenarios – for in-
stance, without a programme targeted at high-risk
individuals or the elderly.
Methods
We performed a cost-effectiveness analysis of alternative
influenza vaccination policies from the perspective of
the health service and personal social services, as recom-
mended in the UK [12].
Vaccination programmes evaluated
We evaluated the impact of the seasonal influenza vac-
cination under seven possible scenarios of extension to
low-risk individuals in the following age groups (ordered
by size: 2–4 years, 50–64 years, 5–16 years, 2–4 and 50–
64 years, 2–16 years, 2–16 and 50–64 years, and 2–64
years) incremental on four different base policies (no
vaccination, risk groups only, risk groups and elderly,
and risk groups and elderly with risk group at 75 %
coverage). The base case of our study is the ‘risk group
and elderly’ policy which was recommended in the UK
from 2000 to the time of this analysis (i.e. 2012). The
coverage of the extended programme is assumed to
reach 50 % while coverage of the base programme is as-
sumed to remain the same as the actual coverage ob-
served in the different years of the study. The detailed
figures of the coverage for the different age- and risk-
groups for the different years of the study were pre-
sented in Table S1 of Baguelin et al. [9]. Coverage
remained modest in low-risk groups but increased stead-
ily in risk groups during the early years of the study fol-
lowing efforts to promote vaccination for individuals at
high risk of complications. In the late years of the study,
risk group vaccination plateaued around 20 % in chil-
dren (aged 1–14 years) and just below 50 % in adults.
Levels of vaccination in the elderly were comparatively
high, remaining constantly between 70–75 % starting
from the 2003/2004 season. In the base case, vaccin-
ation is assumed to be 70 % in the elderly for the year
before the 2000/2001 season when the change of policy
was decided. In the risk group-only base policy, the
coverage in the low-risk elderly is assumed to remain at
29.3 % after 2000, the average coverage in the previous
years in that group.
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As there is significant uncertainty in the coverage that
may be achieved for the extensions, the base-case as-
sumption of 50 % was varied between 15 %, 30 %, and
70 %. The costs of expanding coverage in the high-risk
individuals were assumed to increase linearly with cover-
age (constant marginal returns). The 53 scenarios evalu-
ated are listed in Table 1 with each cell of the table
representing one scenario.
Model
We utilise the reconstructed epidemic profiles from
Baguelin et al. [9] and estimate the number of infections
that occurred for each influenza strain by age and risk
group during the 14-year study period (1995/1996 to
2008/2009) under the actual vaccination programme. In
addition, we use the same model to estimate the number
of infections that would have occurred under other vac-
cination programmes; i.e. if the vaccination programme
had been extended to other (low-risk) age groups. We
repeated this for the other three base programmes (no
vaccination, risk group only, risk group and elderly but
with a 75 % coverage in risk group).
Details of the evidence synthesis and parameter as-
sumptions for the reconstruction of the past epidemics
and the creation of alternative vaccination scenarios
have been described earlier [9]. In brief, the model gen-
erates a sample of epidemiological scenarios for each
type of circulating influenza strain (H1N1, H3N2, and
influenza B) and each of the years of the study by using
an adaptive Markov chain Monte Carlo method. This
gives a set of epidemics, based on the posterior distribu-
tions of the parameters, that reproduces annual strain-
specific epidemiological patterns between 1995 and
2009. For each of these epidemics, alternative vaccine
scenarios are generated by running the same model with
a different vaccine calendar for that year and scenario.
This then generates the estimated number of infections
that would have occurred under alternative strategies.
We assume in the base case that vaccine coverage is
50 % among low-risk groups and that individuals are
immunised in the autumn. Parameters and assumptions
of the transmission model can be found in more details
in Baguelin et al. [9].
Linking estimates of infection risks with disease
burden risks
In addition to the number of infections associated with
each scenario, the number of associated health out-
comes, such as number of clinical cases, general practi-
tioner (GP) consultations, hospitalisations, and deaths,
are estimated. The proportion of clinical cases among
infections is obtained from Carrat et al. [13] (Table 2).
To link the model-derived number of infections to the
other health outcomes (GP consultations, hospitalisa-
tions, and deaths), we use an age-specific (and strain and
risk specific when available) negative binomial regression
model with identity link and intercept. These health out-
comes are taken from Cromer et al. [11] and regressed
in the year they are available using the model estimates
of infection during these years as predictors. This is
similar to the estimation process of the number of
deaths resulting from different vaccine scenarios through
linking of model-derived infection estimates with death
estimates via regression, which has been previously de-
scribed [9]. A major difference between the study by
Baguelin et al. [9] and the present study however, is that
the deaths results used herein were obtained from the
study by Cromer et al. [11], where deaths are defined as
deaths following hospitalisations. This provides a more
conservative estimate than regressing against, for ex-
ample, all-cause mortality. To account for uncertainty in
the estimated number of the different health outcomes
(including deaths) attributable to influenza per year, we
have sampled the estimates from Cromer et al. [11]
using the resulting normal distributions from the regres-
sion study rather the mean estimates. Additionally, the
Table 1 Vaccine strategies evaluated in the study
Base policy
No vaccination Risk group only (Pre-2000 ) Risk group and elderly (Post-2000) Risk group (75 %) and elderly
Extension None X X X X
2–4 years 50 % 50 % 15 % 30 % 50 % 70 % 50 %
50–64 years 50 % 50 % 15 % 30 % 50 % 70 % 50 %
5–16 years 50 % 50 % 15 % 30 % 50 % 70 % 50 %
2–4 and 50–64 years 50 % 50 % 15 % 30 % 50 % 70 % 50 %
2–16 years 50 % 50 % 15 % 30 % 50 % 70 % 50 %
2–16 and 50–64 years 50 % 50 % 15 % 30 % 50 % 70 % 50 %
2–64 years 50 % 50 % 15 % 30 % 50 % 70 % 50 %
Vaccination strategies evaluated in this study. Strategies are built on a base policy and an extension to groups among the population at low risk of complications.
Coverage figures are for the extension while for the base policy historical figures observed other the length of the study are used. A total of 53 scenarios have
been evaluated, each of them represented by a cell in this table
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GP consultation data were not available by risk group
status. The fraction of GP consultations for influenza-
like illness (ILI) attributed by risk group is based on the
risk group prevalence and the relative risk of an ILI con-
sultation in those in any risk group compared to the
low-risk population in an internet-based cohort [14, 15].
Efficacy and cost of vaccines
A recent Cochrane review [16] suggested that vaccine ef-
ficacy was 73 % in years in which the vaccine was well-
matched, and 44 % in years when there was a poor
match between the vaccine and circulating strains. In
addition, a recent analysis by Fleming et al. [17] on sea-
sonal influenza vaccine efficacy, suggested that efficacy
was lower in the elderly (46 %) compared to younger
adults (70 %). Since all of the studies included in the
Cochrane review were performed on healthy young adults,
we assumed that efficacy was 70 % and 46 % in those
under or over 65 years of age, respectively, in a well-
matched year, which was reduced to 42 % and 28 %
in poorly matching years. We assume that children
would be immunized with a live attenuated influenza
vaccine and that this type of vaccine will produce
similar protection to the current trivalent inactivated
vaccine in adults [18].
In the base-case analysis, we also assume that the live
attenuated influenza vaccine (LAIV) used for children
from 2–16 years of age, has a cost per dose similar to
the trivalent inactivated vaccine (Table 2). Costs of the
vaccination programme were guided by the Department
of Health (Stephen Robinson, personal communication).
Delivery costs were estimated to be £9.64 per dose (item
of service payment of £7.64 and dispensing fee of £2
based on the middle of a range set out in Annex G of
the Statement of Financial Entitlements [19, 20]). The
average reimbursement rate (cost per dose of vaccine)
was estimated to be £6.21, giving an overall estimate
of £15.85 per dose of vaccine. This was varied be-
tween £12 and £20 per dose in the probabilistic sen-
sitivity analysis.
Outcome measures and cost effectiveness analysis
Estimates of the health-related quality of life (QoL) loss
associated with non-fatal cases of influenza were taken
from the literature [21, 22] (Table 2). Fatal cases were as-
sumed to also lose the average age- and risk-specific dis-
counted quality-adjusted life expectancy. The risk- and
age-specific life-expectancy was estimated from a survival
analysis of the Royal College of General Practitioners
Weekly Returns Service data from 2005 to 2008, using the
method described by Melegaro and Edmunds [23]. Age-
specific QoL weights were taken from Kind et al. [24],
using the EQ-5D rating scale. Data for children were ab-
sent, and it was assumed that their average QoL weight
was somewhat higher (at 0.9) than in the 18–20 year age
group (the youngest age group sampled). Risk group
specific data were not available, and so both groups were
assumed to have the same average QoL weight. In the
base-case lost life-expectancy (as a result of death from
influenza), was discounted to its present value at a rate of
3.5 % per annum, as recommended by the National
Institute for Health and Care Excellence (NICE) [12].
This was varied as part of the sensitivity analysis.
Influenza seasons vary in severity and, because of this,
programmes can present fluctuations of cost-effectiveness
on a year-to-year basis; in severe years, it is more cost-
effective to vaccinate against influenza than in mild years.
As we are interested in the impact of the programme over
several years independently of year-on-year variations, the
cost per Quality-Adjusted Life Year (QALY) gained are
presented as long-term outcomes, in which the impact is
averaged over a period of 10 years, each of which was
Table 2 Parameters of the economic model
Parameter Estimate Uncertainty Source
Relative risk of consulting
a GP in a risk group
1.51 Normal (μ = 1.51, sd = 0.18) Flusurvey (http://flusurvey.org.uk/) cohort [14]
Cost of vaccination 15.85 Triangular (vertices 12, 15.55, 20) Personal communication (Department of Health)
Febrile cases 0.406 Triangular on [0.309–0.513] Review of volunteer studies [13]
All ARI cases 0.645 Triangular on [0.546–0.733] Review of volunteer studies [13]
QALY loss per non-fatal ILI case 7.49 × 10-3 Bootstrap from data on H1N1 pdm Van Hoek et al. [21]
QALY loss per non-fatal ARI case 1.01 × 10-3 Normal (μ = 1.01 × 10-3, sd = 8.35 × 10-5) Camacho et al. [14]
QALY loss per hospitalisation 0.018 Normal (mu=0.018, sigma=0.0018) Siddiqui et al. [22]
Hospital cost (per episode) £840 Lognormal (normal μ = 839, normal σ = 192.1) Baguelin et al. [7]
GP cost (per consultation) £37 Lognormal (normal μ = 37, normal σ = 8.4) Baguelin et al. [7]
Values of parameters used in the economic model and their associated uncertainty. As part of the probabilistic sensitivity analysis, more uncertainty is added by
using the distributions of estimates from Cromer et al. [11] rather than the mean estimates when estimating the risk of different health outcomes following one
influenza infection
GP, General practitioner; ARI, Acute (non-influenza-like) respiratory infections; ILI, Influenza-like illness; QALY, Quality-adjusted life year
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randomly chosen among the study years. We also assume
in our model that vaccination in a particular year does not
provide protection in the following years. We thus do not
model potential residual protection in the face of waning
antibodies and drift of circulating viruses. Consequently,
the horizon of any studied policy is one season and we do
not need to apply discount rates for costs.
Results are also presented in the form of net benefit
(NB), where QALYs gained are monetised by assuming
that the marginal willingness to pay for a QALY is
£25,000. To ease interpretation, most tables and figures
are presented as changes in the costs and benefits com-
pared with the strategy in place before the decision to
implement a paediatric programme (i.e. the programme
in place before 2013). The policy in place in the UK
prior to 2013 is similar to the WHO recommendation
and will be later referred in this paper as the elderly-
and risk-group programme. In addition to comparing al-
ternative programmes to this elderly- and risk-group
programme, an incremental analysis is also performed
(Table 3) in which the alternatives are ranked in terms
of net costs and the additional benefits and costs of the
next most costly strategy is compared, having removed
dominated alternatives. We performed probabilistic sen-
sitivity analysis for the economic model using the applic-
able distributions for the different parameters (Table 2).
Sensitivity analysis
Net benefit derived from an extension of the programme
to children
We assessed the benefit derived from an extension of
the programme to children (in terms of non-fatal and
death-associated QALYs gained per year and individual)
in the different age- and risk-groups for the extension to
2–16-year-old, low-risk children. We derived the benefit
to children using two methods.
In the first method, we used a simple calculation using a
conservative estimate of the cost and QALYs gained
through the direct effect of the programme for one
vaccinated child. For this, we divided the cost of the vac-
cine (an upper boundary of cost as cost would be saved
through reduced GP consultations and hospitalisations) by
the average differential QALY directly gained per vacci-
nated child. The differential direct QALY per child was
equal to the vaccine efficacy multiplied by the probability
of developing clinical symptoms (clinical attack rate) and
the QALY loss per febrile episode. From this, we derived a
conservative minimum attack rate sufficient for the
programme to be cost-effective from the direct effect
alone.
In the second method, we calculated the group specific
incremental cost effectiveness ratio (ICER) and NB by
restricting the benefits to those gained in the 2–16 age
group. We also calculated what should be the QALY loss
associated with LAIV vaccination necessary to cancel
the positive impact (in term of NB) in this age group.
Sensitivity to the cost of the vaccine
To reflect that the vaccination programme in children
might result in higher cost per vaccine dose (whether
because of a different delivery model or price per dose),
we also performed a sensitivity analysis to vaccine costs;
as an alternative to the base case we assume that the
costs per dose would increase by £6 in children, bringing
the overall cost per dose to be £21.85 in this age group.
The choice of increasing by £6, though relatively arbi-
trary, reflects a plausible increase of almost 40 % com-
pared with the adult cost per dose.
Sensitivity to non-influenza-like acute respiratory
infections (ARIs)
In the base case, we adopted the conservative position of
ignoring the QALY losses associated with acute (non-
influenza-like) respiratory infections (ARI). There is
little information on the QALY losses associated with
ARI to attribute these episodes to influenza. In the sensi-
tivity analysis, we included non-fatal ARI QALY losses
through combining recently estimated QALY losses asso-
ciated with ARI [14] and estimates of the fraction of infec-
tions that lead to non-febrile ARI [13].
Results
Impact and cost effectiveness of the elderly- and
risk-group programme
We calculated the age-specific attack rates during the
period of the study defined as the proportion in a given
age group experiencing a febrile episode due to one of
the three circulating strains of influenza. Results from
the model show that the most affected age group in
terms of clinical attack rates are children aged 5–14
(15 %) due to high contact rates and limited immunity.
The 15–44 and the 6-month to 4-year-old age groups ex-
perience similar levels with 13 % and 11 % of attack rates,
Table 3 Incremental cost-effectiveness ratios (ICERs)
Increment ICER
(£/QALY)
Net benefit
in £M
95 % credibility
interval
Elderly- and risk-group → 2–4 y 2,613 74 (12–265.7)
2–4 y → 5–16 y 1,569 384.4 (85.4–1309.6)
5–16 y → 2–16 y 3,414 58.7 (8.4–212.8)
2–16 y → 2–16 y & 50–64 y 8,093 75.9 (–11.5 to 346.1)
2–16 y & 50–64 y → 2–64 y 8,868 198.8 (–46.8 to 950.8)
Table of the incremental cost-effectiveness ratios and net benefit for the proposed
immunization strategies. Strategies are ordered in terms of their net cost, and the
incremental costs and incremental benefits of the next most expensive strategy is
compared with the previous one. Dominated strategies (50–64 year age group and
2–4 and 50–64 year age groups) have been excluded
QALY, Quality-adjusted life year
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respectively, while the youngest and eldest age groups
present smaller attack rates due to less contact and immun-
ity from either maternal antibodies, past history of exposure
to circulating viruses, or immunisation (0–6 months, 7.7 %;
45–64 years, 7.5 %; and over 65 years, 2.6 %). Table 4 sum-
marises the results of the model in terms of disaggregated
outcomes (annual numbers of cases, hospitalisations,
costs, QALYs gained, etc.) for each of the strategies. From
the results of the first two columns it can be seen that,
compared with no vaccination, the elderly- and risk-group
influenza programme is likely to be cost effective (ICER:
7475 £/QALY, NB: 253 M£ [15–829]).
Cost effectiveness of the possible extensions
The extensions to the elderly- and risk-group programme
are presented in the seven right-hand columns of Table 4.
They are ordered in terms of their net cost from left to
right. Hence, vaccination of the low-risk pre-school chil-
dren is the least expensive extension, followed by vaccin-
ation of the 50–64 year age group and so on. There is a
general trend for the more expensive options to be more
effective (reducing cases, deaths and QALYs lost more
than the cheaper alternative), but this is not always the
case. Vaccination of school children, for instance, results
in fewer cases and deaths than vaccination of 2–4
Table 4 Summary results of model
Scenario Elderly- and
risk-group
No vaccination 2–4 y 50–64 y 5–16 y 2–4 & 50–64 y 2–16 y 2–16 & 50–64 y 2–64 y
Cases mean (000s) 5,325 6,474 4,914 4,668 2,882 4,269 2,559 1,971 322
Low 3,787 4,641 3,506 3,268 1,764 3,006 1,513 1,075 30
High 7,137 8,548 6,544 6,323 4,215 5,760 3,780 3,044 816
GP mean 603,095 721,152 539,893 541,134 313,892 480,317 264,246 207,979 37,544
Low 368,255 451,303 323,362 321,755 169,135 283,818 133,495 95,343 3,383
High 916,405 1,056,782 822,924 826,488 536,822 737,721 458,143 377,580 95,980
Hospitalisations mean 11,957 16,259 10,348 10,648 7,024 9,113 5,812 4,635 1,166
Low 6,861 9,439 5,951 5,993 3,279 5,079 2,509 1,778 59
High 19,152 26,641 16,820 17,307 12,299 14,952 10,468 8,753 3,223
Death mean 1,784 2,917 1,668 1,568 1,099 1,454 985 778 179
Low 643 1,081 602 573 346 530 289 198 6
High 3,930 6,440 3,677 3,386 2,507 3,180 2,268 1,887 625
Non death QALYs mean 40,514 49,365 37,375 35,495 21,896 32,450 19,446 14,946 2,429
Low 3,852 4,752 3,555 3,353 2,054 3,087 1,794 1,337 81
High 126,421 152,964 115,649 111,676 67,157 101,865 58,597 45,899 10,242
Death associated QALYs mean 13,554 21,660 12,684 11,932 8,371 11,073 7,508 5,936 1,316
Low 5,711 8,669 5,279 4,917 2,962 4,497 2,561 1,791 52
High 28,198 44,823 26,431 24,196 17,590 22,877 16,155 13,454 4,465
QALYs loss total mean 54,068 71,025 50,059 47,426 30,267 43,523 26,953 20,882 3,745
Low 13,253 19,358 12,387 11,767 7,954 10,915 6,940 5,336 380
High 141,995 177,528 131,318 125,105 76,379 114,248 68,559 52,870 11,601
Mean programme cost (£K) 134,817 – 149,012 187,054 191,283 201,248 205,477 257,714 418,988
Low 105,494 – 117,032 147,680 151,915 159,480 163,653 206,070 335,773
High 163,856 – 180,742 225,997 230,463 242,665 247,481 309,787 502,957
HC cost mean (£K) 32,607 40,664 28,886 29,184 17,669 25,615 14,788 11,687 2,378
Low 18,591 24,017 16,432 16,079 8,932 14,163 7,101 4,961 173
High 54,172 66,369 48,275 48,485 31,087 42,387 26,175 21,276 6,130
Cost total mean (£K) 167,425 40,664 177,898 216,238 208,952 226,863 220,265 269,401 421,366
Low 124,085 24,017 133,464 163,758 160,847 173,642 170,753 211,031 335,946
High 218,027 66,369 229,018 274,482 261,551 285,052 273,656 331,063 509,087
The average annual number of influenza-like illness (febrile) cases, GP consultations, etc. are shown along with measures of their distribution for each of the
strategies (columns)
GP, General practitioner; QALY, Quality-adjusted life year
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and 50–64 year olds is estimated to, although targeting
fewer individuals. Note that a large proportion of the
QALYs lost (~25 %) is estimated to be due to deaths. Note
also that the majority of the net costs of the programme
are associated with the cost of vaccination. Savings (in
terms of health care costs) are relatively small.
Extension of the elderly- and risk-group immunisation
strategy against seasonal influenza to either one of the
target groups defined earlier is likely to be cost-effective
(Fig. 1). However, strategies that do not include the vac-
cination of school-aged children are less likely to be
cost-effective. The most efficient strategy is extension to
5–16-year-old children while universal vaccination will
achieve the highest NB (Table 5).
We estimated the incremental cost effectiveness ratios
and NBs of the vaccination scenarios in the order of in-
creasing costs of the programmes (Fig. 1 and Table 3).
Dominated strategies were excluded. Gradual extension
of the programme to all children is cost effective. Inclu-
sion of children aged 5–16 years was found to be the
most cost effective extension in the incremental ana-
lysis. Further extension to adults and even all indi-
viduals remains cost effective. However, it should be
noted that more than 10 % of simulations fail to be
cost-effective.
Re-evaluation of historical changes
Extending the programme in the UK in 2000 from a
risk-group-specific strategy to include those aged 65
years of age and over is likely to have been marginally
cost-effective but with significant uncertainty (ICER:
17,023 £/QALY, NB: 12.2 M£ [–18.6 to 66]). We find
that an extension to children aged 2–16 years would
have been a more cost effective extension of the
programme at an ICER of 2,555 £/QALY (NB: 526.4 M£
[96–1824]).
Strategies incremental on no vaccination
In the absence of an existing programme, implementing
first the routine vaccination of children is estimated to
be more cost-effective than adopting a risk-based policy
as implemented in the UK pre-2000; however, the risk-
based policy is cost effective as well. For the vaccination
of 2–16-year-old, low-risk children alone we estimate an
ICER of 1,679 £/QALY (NB: 610 M£ [145–1975]) while
the pre-2000 policy of targeting mainly risk groups is es-
timated at 6,231 £/QALY (NB: 242 M£ [28–780]). If
childhood vaccination had been in place (targeting the
2–16 year age group), it would still have been cost-
effective to extend the programme to include risk groups
(incremental ICER of 9,215 £/QALY, NB: 160 M£ [–19
Fig. 1 Incremental analysis with costs and quality-adjusted life years (QALYs) gained. Estimated change in costs and QALYs gained over the
elderly- and risk-group strategy, for each of the extensions to the vaccination programme. Note that the comparison in each case is with the
elderly- and risk-group strategy. Each contour line represents 90 % of the Monte Carlo simulations with the coloured point inside being the mean
outcome of the scenario. The two diagonal lines represent £20,000 (solid) and £30,000 per QALY gained. Unfilled circles indicate strategies which
are dominated by others. The arrows indicate the pathway of increasing costs for the incremental analysis
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to 623]) and then to incorporate the elderly (incremental
ICER of 16,482 £/QALY, NB: 5 M£ [–14 to 39]), though
this last step would have provided much smaller benefits
and uncertain cost effectiveness (32 % of simulations are
not under a threshold of 25,000 £/QALY).
Scenario and sensitivity analysis
Discount rates and baseline of coverage in risk-groups
Table 5 (a–c) presents the sensitivity of our model esti-
mates to the assumed discount rate. In each case, exten-
sions of the vaccination programme from the elderly- and
risk-group strategy are shown (i.e. no incremental
analysis). Reducing the discount rate increases the cost-
effectiveness of extending vaccination, as more QALYs are
gained. However, earlier conclusions from the base case re-
main robust to changes in discount rates. Equally, base case
results are robust to the change in baseline coverage in risk
groups. Even with a coverage of 75 % in risk groups conclu-
sions regarding incremental and individual benefits of the
different extensions remained unchanged, although with
slightly higher ICERs and lower NBs.
We compared an extension to the low-risk 2–16-year-
olds with an increase in vaccine coverage in high-risk
groups to the target level of 75 % (both incremental on
the elderly- and risk-group programme). The 2–16 low-
risk strategy appears marginally more cost effective with
an ICER of 1949 £/QALY (NB 521 M£ [104; 1785])
compared with the ICER of 2193 £/QALY (NB 200 M£
[42; 649]) associated with increasing vaccine coverage
within the at risk population.
Sensitivity to the level of coverage in the low-risk groups
We estimated the NB of extending vaccination to the
low-risk groups at different levels of coverage for the
seven different strategies (Fig. 2). For all strategies but
the universal one (extension to 2–64 years) the costs
and the benefits increase with increasing coverage. How-
ever, the benefits increase at a higher rate, due to in-
creasing herd protection in the unvaccinated and the
vaccinated but not protected. For a universal vaccin-
ation programme, a turning point is reached at around
50 %, from where increasing coverage decreases the
Table 5 Sensitivity to discount rates and coverage in risk groups
a) 3.5 % discount (Base case)
Extension to 2–4 50–64 5–16 2–4 + 50–64 2–16 2–16 + 50–64 2–64
ICER 2613 7350 1745 5637 1949 3073 5046
Net benefit in mil £ 74 91 460 164 521 604 819
Lower 12 –8 94 9 104 93 65
Higher 266 385 1577 614 1785 2107 3046
b) 1.5 % discount
Extension to 2–4 50–64 5–16 2–4 + 50–64 2–16 2–16 + 50–64 2–64
ICER 2509 7030 1675 5398 1869 2943 4818
Net benefit 79 99 487 177 551 642 875
Lower 15 –2 115 17 126 118 108
Higher 272 394 1615 626 1820 2141 3090
c) 0 % discount
Extension to 2–4 50–64 5–16 2–4 + 50–64 2–16 2–16 + 50–64 2–64
ICER 2406 6715 1604 5162 1788 2813 4590
Net benefit 83 107 515 190 584 680 941
Lower 18 3 135 25 148 153 159
Higher 276 401 1643 639 1864 2174 3139
d) Risk groups vaccinated with a 75 % coverage
Extension to 2–4 50–64 5–16 2–4 + 50–64 2–16 2–16 + 50–64 2–64
ICER 2748 8677 2393 6655 2618 3844 6667
Net benefit 72 86 417 158 463 520 592
Lower 11 –17 71 –3 75 59 –17
Higher 258 381 1438 600 1607 1847 2411
Cost-effectiveness ratios (compared with the elderly- and risk-group strategy) and net benefits with associated 95 % credibility intervals using different discount
rates (a–c) for future benefits (QALYs) and a different baseline (d) for the coverage in risk-groups (75 %)
ICER, Incremental cost effectiveness ratio
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total NB (though benefits in term of QALY gained
still increase).
Benefits derived from vaccination of children
Results from simple direct conservative calculation ignor-
ing cost saved by reduced GP consultations and hospitali-
sations using cost and QALY parameters from Table 2
indicates that, for a threshold of £25,000/QALY, the vac-
cination programme would be cost-effective from its direct
effect if more than 12 % of the child population is affected
by at least one strain of influenza during the season.
We further studied the age, risk, and outcome-
associated distribution of Quality-Adjusted Life Days
(QALD) as a result of extending the programme to in-
clude low-risk children aged 2–16 years (Fig. 3). Most of
the death-associated QALD gains are indirect gains in the
unvaccinated population. They are concentrated in the
risk groups, in particular in the elderly (65+) and younger
adults (15–44) who are more likely to be in contact with
children and in the low-risk elderly. The gain in non-fatal
QALDs is more widely spread across the population but is
highest in vaccine-targeted children aged 5–14 years and
benefiting both the low-risk and the risk group of the
same age (not targeted by the extension).
If one was to ignore any indirect protection, extending
the elderly- and risk-group programme to children 2–16
years of age only for the benefit of these children (2–16
years), we estimate that the extension would still be cost
effective. At full costs but only accounting for benefits
in 2–16-year-olds, the ICER would reduce to 7,713
£/QALY and the mean NB to £81m (90 % CI –£31 to
£400m). In order for the mean benefit to be offset by
the QALY loss associated with LAIV vaccination (still
at full costs and only accounting for benefits in the
2–16 year age group), each vaccinated child should experi-
ence a health loss of 0.39 QALD from vaccination.
Additional benefits due to preventing non-influenza-like ARI
In the main case, we quantify the QALY loss due to in-
fluenza infection using febrile episodes. In Fig. 3, we
show the QALY loss in the different age groups associ-
ated with non-febrile acute ARI, indicating that non-
fatal QALY loss is mainly associated with febrile episode
though non-fatal ARI-associated QALY loss will account
for an additional 10 % of non-death QALY loss.
Discussion
We find that the strategy of vaccinating high-risk indi-
viduals and those over the age of 65 years against influ-
enza is cost-effective. This is despite the low level of
effectiveness assumed for vaccination of the elderly and
the variability in impact from year to year. However, the
extension of the UK programme in 2000 to include indi-
viduals over the age of 65 years, similar to current WHO
recommendations, may not have made optimal use of
resources. Although we find that this extension was cost
effective, an alternative extension to children would have
yielded a substantially higher NB.
Assessing whether the programme should be further
expanded to other low-risk groups, we find that annual
Fig. 2 Incremental net benefit over the elderly- and risk-group programme. Incremental net benefit of different extension over the elderly- and
risk-group programme for different levels of coverage (left panel) and net benefit for the base case at 50 % coverage (right panel). Dominated
scenario are indicated by empty disk and bars
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vaccination of children aged 5–16 years is the most
cost effective option. Furthermore, vaccination of
children is likely to be more cost-effective and to
provide greater NB than improving coverage in the
high-risk groups. Much of the impact of childhood
vaccination for influenza relies on indirect protection
of the community through reduced transmission.
However, we find that the vaccination of children re-
mains cost effective even if indirect effects were not
taken into account. A simple conservative calculation
indicates that if the attack rate in unvaccinated chil-
dren is higher than 12 %, the policy is likely to be
cost-effective even without taking into account indirect
effects. Attack rates in excess of this level are likely in
most seasons [25].
Strength and weaknesses
This study is based on a transmission model fitted to 14
years of surveillance data and hence captures substantial
amounts of inter-season variability and provides realistic
parameters. It also captures the indirect impact of
vaccination which allows us to distinguish between the
benefits coming from direct and indirect protection.
However, influenza viruses are constantly evolving and
there is a chance that childhood vaccination, while retro-
spectively the best option, may not be optimal for
Fig. 3 Benefits from extension to low-risk 2–16-year-old children. Benefits (in terms of non-death and death-associated Quality-Adjusted Life Days
per year and per person of that age and risk group) gained from extension of vaccination to low-risk 2–16-year-old children. The benefit is given
for each age and risk group (pink bars low risk, blue bars high risk). Note the change of scale in the last panel
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future seasons if the influenza epidemiology changes
substantially.
Much of the benefits derived from a childhood vac-
cination programme accrue to other age groups (in par-
ticular the high-risk adults). Therefore, assumptions
regarding contact patterns are important. In this study,
we used contemporary data on underlying social con-
tacts [26] as input parameters into the model (priors),
and further refined our estimates during the extensive
model fitting procedure [9] (giving posterior distribu-
tions for these parameters). The method should there-
fore ensure that the resulting parameter estimates are
relatively robust. Furthermore, the remaining uncer-
tainty in these critical parameters is passed through the
economic analysis. The policy choice does seem to be
relatively insensitive to this (i.e. there is a relatively
high probability that vaccination of children would be
deemed cost-effective at £20–30,000 per QALY gained).
Nevertheless, vaccination of children to prevent influ-
enza in the population at large is controversial. A num-
ber of studies have suggested that it may be effective,
although the standard of evidence has generally been
weak. The essential interruption of transmission of the
2009 pandemic virus by the summer holidays in the UK
[27] shows the impact that school children can have on
the epidemiology of influenza in the UK, and lends sup-
port to the hypothesis that vaccination of these age
groups may well bring significant benefits to others in
the population. With the recent recommendation to
vaccinate all children in the US, it is envisaged that fur-
ther data may be forthcoming on this in the near fu-
ture. It is also important to note that the benefit
restricted to this age group alone is sufficient to make
the child vaccination programme cost-effective even
without taking into account the benefits in the other
age groups.
As recommended by NICE [12], we took the perspec-
tive of the health care provider. It is possible that by
restricting our attention to health-care costs, we have
significantly underestimated the benefits of influenza
vaccination. If a wider societal perspective had been
taken (which would therefore include the costs of absen-
teeism, etc.), vaccinating low-risk adults would be made
more cost-effective, possibly changing our conclusions
about the economic attractiveness of the option.
It is possible that the analysis presented here underes-
timates the benefits of extending influenza vaccination
to low-risk groups. The burden associated with the epi-
demics related to the three influenza subtypes circulat-
ing may be underestimated in this analysis [11]. For
instance, the death rates were estimated from an analysis
of the hospitalisation data, not all cause mortality, which
would result in a far higher number of deaths being
attributed to influenza, than was used herein [11]. In
addition, the QoL loss associated with non-febrile cases
is not included in the main analysis due to a lack of data
on this [21], even though roughly one-third of all infec-
tion cases do not result in classical ILI symptoms [28].
Further, the QALY loss associated with non-hospitalised
disease relies on one study only, based on confirmed
cases during the 2009 influenza pandemic [21]. Though
we have bootstrapped the data from this study to ac-
count for uncertainty, additional estimates resulting
from infection by other strains would have allowed us to
get stronger confidence in the exact loss of QALYs asso-
ciated to non-fatal influenza cases and possible variation
between strains. Taken together, it is likely that these re-
sults are therefore conservative. Nevertheless, the con-
clusions with regards to childhood vaccination are
unlikely to be affected by these possible biases, since it
appears that this strategy is likely to be cost-effective.
In our model, the vaccine is assumed to work by redu-
cing transmission and vaccine efficacy is interpreted ac-
cordingly. Other modes of action of the vaccine might
be consistent with observations of vaccination, such as
reduction in probability or severity of symptoms. If vac-
cination was to reduce symptoms but not transmission,
our conclusions would potentially need to be altered by
considerably reducing the impact of the indirect protec-
tion provided by mass vaccination campaigns.
The model on which this study is built considers the
benefits over each individual season and averages these
benefits over a 14-year period. It does not consider the
impact of repeated vaccinations and the associated ef-
fect on immunity in the population. Whether there will
be additional benefits from protection carried forward
from previous years, or a potential risk of increased
susceptibility in the population due to a lack of expos-
ure in the unvaccinated because of herd protection, is
uncertain. An extension of our model framework to in-
clude immunity from natural exposure and vaccination
and linking the seasons could potentially provide
further insight.
Comparison with other studies
A number of recent studies have attempted to estimate
the cost-effectiveness of extending influenza vaccination
over the age- and risk-group-specific policy [29–41].
These studies have either looked at extending vaccin-
ation to children [34–40], or adults aged 50–64 years
[29–33], or in one case universal vaccination [41]. How-
ever, to our knowledge, no previous study has assessed
the cost-effectiveness of all of these options in a single
analysis. That is, no previous study has fully assessed the
opportunity cost of extending vaccination by looking at
alternative uses. Taken in isolation, for instance, vaccin-
ation of 50–64-year-olds may appear marginally cost-
effective (see Table 3 which is broadly in line with the
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findings of other studies [29–33]), but when compared
with vaccination of children it is dominated. A further
strength is the use of a transmission dynamic frame-
work, which is able to estimate the direct and indirect
(herd-immunity) effects that may result from influenza
vaccination. With very few exceptions [37, 38], model-
based evaluations of influenza vaccination (reviewed in
Peasah et al. [42]) uses static decision-analytic models,
which ignore the effect that vaccination may have on
others in the community. This leads to, for instance, the
finding that vaccination of younger children is more
cost-effective than school-aged children [34], as the bur-
den of disease in younger children is greater. Our study
suggests the opposite, as the increased indirect effect
resulting from vaccination of school children compared
to pre-schoolers exceeds the decreased direct effect. Not
only did we use a transmission dynamic model, but we
fitted this to a range of surveillance data using Bayesian
methods [9]. Most previous economic models of influ-
enza vaccination have relied on parameter values taken
from the literature, rather than attempt to fit their
models to a range of data, giving updated and refined
parameter estimates and further confidence in results.
Conclusions
Making use of surveillance data from over a decade in
conjunction with a dynamic model, we find that vaccin-
ation of children in the UK is likely to be highly cost-
effective, not only for their own benefit but also to reduce
the disease burden in the rest of the community. The Joint
Committee on Vaccination and Immunisation has recently
decided to extend the influenza immunisation programme
in the UK to all children aged 2–17 years [10]. The work
presented here has helped shape this decision. This sug-
gests that, in countries where children are similarly a main
source for the transmission of influenza, childhood vaccin-
ation against seasonal influenza may present an opportun-
ity to prevent a higher burden of disease at similar cost to
vaccination of the elderly.
Abbreviations
ARI: Acute (non-influenza-like) respiratory infections; GP: General practitioner;
ICER: Incremental cost effectiveness ratio; ILI: Influenza-like illness; LAIV: Live
attenuated influenza vaccine; NB: Net benefit; NICE: National institute for health
and care excellence; QALD: Quality-adjusted life days; QALY: Quality-adjusted life
year; QoL: Quality of Life; TIV: Trivalent inactivated vaccine; UK: United Kingdom;
WHO: World Health Organization.
Competing interests
WJE’s partner works for GlaxoSmithKline. The other authors do not have
competing interests.
Authors’ contributions
Conceived and designed the experiments: MB, WJE. Performed the experiments:
MB, AC, SF. Analyzed the data: MB, AC, SF, WJE. Wrote the first draft of
the manuscript: MB, WJE. Contributed to the writing of the manuscript:
MB, AC, SF, WJE. ICMJE criteria for authorship read and met: MB, AC, SF,
WJE. All authors read and approved the final manuscript.
Acknowledgements
Douglas Fleming for giving us access to the RCGP data, Joanna Ellis for
advice and data on matches between the vaccine and circulating strains,
Richard Pebody for vaccine uptake data, and Praveen Sebastianpillai and
Maria Zambon for virological sample results. We also thank Elizabeth Miller,
Richard Pebody, and Mary Ramsay for useful discussions. AC was supported
by the Medical Research Council (fellowship MR/J01432X/1). This research
was part funded (MB) by the National Institute for Health Research Health
Protection Research Unit (NIHR HPRU) in Immunisation at the London School
of Hygiene and Tropical Medicine in partnership with Public Health England
(PHE). The views expressed are those of the authors and not necessarily
those of the NHS, the NIHR, the Department of Health or Public Health
England. The funders had no role in study design; in the collection, analysis,
and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication.
Received: 12 May 2015 Accepted: 14 August 2015
References
1. World Health Organisation. Influenza Vaccines – WHO Position Paper.
Geneva: WHO; 2005.
2. Mereckiene J, Cotter S, D’Ancona F, Giambi C, Nicoll A, Lévy-Bruhl D, et al.
Differences in national influenza vaccination policies across the European
Union, Norway and Iceland 2008–2009. Eurosurveillance. 2010;15:1–10.
3. World Health Organisation. Weekly epidemiological record, vol. 87. Geneva:
WHO; 2012. 21 (pp 201–216).
4. Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the
impact of childhood influenza vaccination programmes in England and
Wales. Vaccine. 2008;26:5321–30.
5. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM. Strategies for
pandemic and seasonal influenza vaccination of schoolchildren in the
United States. Am J Epidemiol. 2009;170:679–86.
6. Cauchemez S, Valleron A-J, Boëlle P-Y, Flahault A, Ferguson NM. Estimating
the impact of school closure on influenza transmission from Sentinel data.
Nature. 2008;452:750–4.
7. Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of
the seasonal influenza vaccination programme in England. Vaccine.
2012;30:3459–62.
8. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJD, et al. Effect
of influenza vaccination of children on infection rates in Hutterite
communities: a randomized trial. JAMA. 2010;303:943–50.
9. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ.
Assessing optimal target populations for influenza vaccination programmes:
an evidence synthesis and modelling study. PLoS Med. 2013;10:e1001527.
10. JCVI statement on the annual influenza vaccination programme – extension of
the programme to children. 2012. http://webarchive.nationalarchives.gov.uk/
20130402145952/http://media.dh.gov.uk/network/261/files/2012/07/jcvi-
statement-on-the-annual-influenza-vaccination-programme-25-july-2012.pdf.
11. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden
of influenza in England by age and clinical risk group: A statistical analysis
to inform vaccine policy. J Infect. 2014;68:363–71.
12. National Institute for Health and Clinical Excellence. Guide to the methods
of technology appraisal. 2013. https://www.nice.org.uk/article/pmg9/
chapter/foreword.
13. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al.
Time lines of infection and disease in human influenza: a review of
volunteer challenge studies. Am J Epidemiol. 2008;167:775–85.
14. Camacho A, Eames K, Adler A, Funk S, Edmunds J. Estimation of the quality
of life effect of seasonal influenza infection in the UK with the internet-
based Flusurvey cohort: an observational cohort study. Lancet. 2013;382:S8.
15. Adler AJ, Eames KTD, Funk S, Edmunds WJ. Incidence and risk factors for
influenza-like-illness in the UK: online surveillance using Flusurvey.
BMC Infect Dis. 2014;14:232.
16. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer G a, Al-Ansary L A, Ferroni E.
Vaccines for preventing influenza in healthy adults. Cochrane Database Syst
Rev. 2010;(7):CD001269.
17. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ,
et al. Estimating influenza vaccine effectiveness using routinely collected
laboratory data. J Epidemiol Community Health. 2010;64:1062–7.
Baguelin et al. BMC Medicine  (2015) 13:236 Page 12 of 13
18. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, et al.
Efficacy of live attenuated influenza vaccine in children: a meta-analysis of
nine randomized clinical trials. Vaccine. 2009;27:1101–10.
19. National Health Service England. Enhanced Services Specification: Seasonal
Influenza and Pneumococcal Immunisation Enhanced Service. 2014.
http://www.england.nhs.uk/wp-content/uploads/2014/06/flu-pneumo-
immu-spec.pdf.
20. National Health Service England. General Medical Services Statement of
Financial Entitlements Directions 2014. 2014. https://www.gov.uk/
government/uploads/system/uploads/attachment_data/file/299591/
SFE_amend_directions_2014.pdf.
21. Van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ. The impact of
pandemic influenza H1N1 on health-related quality of life: a prospective
population-based study. PLoS One. 2011;6:e17030.
22. Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral stockpiling and
near-patient testing for potential influenza pandemic. Emerg Infect Dis.
2008;14:267–74.
23. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide
vaccine. Part II. A cost-effectiveness analysis for invasive disease in the
elderly in England and Wales. Eur J Epidemiol. 2004;19:365–75.
24. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status:
results from a United Kingdom national questionnaire survey. BMJ.
1998;316:736–41.
25. Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ,
et al. Comparative community burden and severity of seasonal and
pandemic influenza: results of the Flu Watch cohort study. Lancet Respir
Med. 2014;2:445–54.
26. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social
contacts and mixing patterns relevant to the spread of infectious diseases.
PLoS Med. 2008;5:e74.
27. Baguelin M, Van Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ.
Vaccination against pandemic influenza A/H1N1v in England: a real-time
economic evaluation. Vaccine. 2010;28:2370–84.
28. Newcombe RG. Interval estimation for the difference between
independent proportions: comparison of eleven methods. Stat Med.
1998;17:873–90.
29. Mogasale V, Barendregt J. Cost-effectiveness of influenza vaccination of
people aged 50-64 years in Australia: results are inconclusive. Aust N Z J Public
Health. 2011;35:180–6.
30. Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness
of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine.
2010;28:7620–5.
31. Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR. The cost-
effectiveness of a universal influenza vaccination program for adults aged
50-64 years in Australia. Vaccine. 2008;26:2142–53.
32. Aballéa S, De Juanes JR, Barbieri M, Martin M, Chancellor J, Oyagüez I, et al.
The cost effectiveness of influenza vaccination for adults aged 50 to 64
years: a model-based analysis for Spain. Vaccine. 2007;25:6900–10.
33. Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, et al. The
cost-effectiveness of influenza vaccination for people aged 50 to 64 years:
an international model. Value Health. 2007;10:98–116.
34. Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, et al.
Effects of adverse events on the projected population benefits and cost-
effectiveness of using live attenuated influenza vaccine in children aged 6
months to 4 years. Arch Pediatr Adolesc Med. 2011;165:112–8.
35. Salleras L, Navas E, Domínguez A, Ibáñez D, Prat A, Garrido P, et al.
Economic benefits for the family of inactivated subunit virosomal influenza
vaccination of healthy children aged 3-14 years during the annual health
examination in private paediatric offices. Vaccine. 2009;27:3454–8.
36. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-
effectiveness of live attenuated influenza vaccine versus inactivated
influenza vaccine among children aged 24-59 months in the United States.
Vaccine. 2008;26:2841–8.
37. Schmier J, Li S, King JC, Nichol K, Mahadevia PJ. Benefits and costs of
immunizing children against influenza at school: an economic analysis
based on a large-cluster controlled clinical trial. Health Aff (Millwood).
2008;27:w96–104.
38. Pradas-Velasco R, Antoñanzas-Villar F, Martínez-Zárate MP. Dynamic
modelling of infectious diseases: an application to the economic evaluation
of influenza vaccination. Pharmacoeconomics. 2008;26:45–56.
39. Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ.
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in
preventing influenza in young children attending day-care centres.
Vaccine. 2007;25:8010–20.
40. Marchetti M, Kühnel UM, Colombo GL, Esposito S, Principi N. Cost-
effectiveness of adjuvanted influenza vaccination of healthy children 6
to 60 months of age. Hum Vaccin. 2007;3:14–22.
41. Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, et al.
Economic appraisal of Ontario’s Universal Influenza Immunization Program:
a cost-utility analysis. PLoS Med. 2010;7:e1000256.
42. Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson M-A.
Influenza cost and cost-effectiveness studies globally – a review. Vaccine.
2013;31:5339–48.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Baguelin et al. BMC Medicine  (2015) 13:236 Page 13 of 13
